Home Online Features TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
Press Releases
TransCode Therapeutics, Inc.  
May 1, 2025

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

A total of 13 patients treated with four escalating doses of TTX-MC138No significant safety or dose limiting toxicities reportedTwo patients have so far maintained stable disease on treatment for at

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social